Sequoia Financial Advisors LLC Buys 501 Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Sequoia Financial Advisors LLC boosted its stake in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 3.6% during the 4th quarter, HoldingsChannel.com reports. The fund owned 14,294 shares of the company’s stock after purchasing an additional 501 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Dr. Reddy’s Laboratories were worth $995,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. FSC Wealth Advisors LLC bought a new stake in Dr. Reddy’s Laboratories in the third quarter valued at $40,000. Harbour Investments Inc. grew its position in shares of Dr. Reddy’s Laboratories by 2,884.6% in the 3rd quarter. Harbour Investments Inc. now owns 776 shares of the company’s stock worth $52,000 after buying an additional 750 shares during the period. Ronald Blue Trust Inc. grew its position in shares of Dr. Reddy’s Laboratories by 84.8% in the 3rd quarter. Ronald Blue Trust Inc. now owns 1,905 shares of the company’s stock worth $120,000 after buying an additional 874 shares during the period. Tower Research Capital LLC TRC grew its position in shares of Dr. Reddy’s Laboratories by 3,440.0% in the 3rd quarter. Tower Research Capital LLC TRC now owns 1,947 shares of the company’s stock worth $130,000 after buying an additional 1,892 shares during the period. Finally, Wells Fargo & Company MN grew its position in shares of Dr. Reddy’s Laboratories by 103.5% in the 2nd quarter. Wells Fargo & Company MN now owns 3,064 shares of the company’s stock worth $193,000 after buying an additional 1,558 shares during the period. Institutional investors own 14.02% of the company’s stock.

Dr. Reddy’s Laboratories Stock Performance

Shares of RDY stock opened at $71.42 on Monday. Dr. Reddy’s Laboratories Limited has a one year low of $53.12 and a one year high of $77.72. The company’s 50-day moving average is $74.65 and its 200 day moving average is $70.09. The company has a market capitalization of $11.92 billion, a price-to-earnings ratio of 18.84, a price-to-earnings-growth ratio of 1.78 and a beta of 0.58. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.90 and a current ratio of 2.55.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its quarterly earnings data on Wednesday, January 31st. The company reported $0.99 EPS for the quarter, beating the consensus estimate of $0.88 by $0.11. Dr. Reddy’s Laboratories had a net margin of 19.26% and a return on equity of 20.97%. The company had revenue of $867.00 million for the quarter, compared to the consensus estimate of $827.81 million. Sell-side analysts expect that Dr. Reddy’s Laboratories Limited will post 3.96 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Jefferies Financial Group downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to an “underperform” rating in a research report on Thursday, January 11th. StockNews.com raised shares of Dr. Reddy’s Laboratories from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 5th. Finally, Barclays upped their target price on shares of Dr. Reddy’s Laboratories from $75.00 to $80.00 and gave the stock an “overweight” rating in a research report on Monday, January 29th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $80.00.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.